CJC-1295

CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH) that increases plasma levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).

Structure

29–amino acid peptide based on GHRH(1-29).
DAC vs. no DAC:

No DAC: Short-acting, half-life ~20–30 minutes, modestly extends natural GHRH activity.
With DAC: Includes a Drug Affinity Complex (DAC) that binds reversibly to serum albumin, extending the half-life to 5–8 days and sustaining physiologic GH pulsatility.

Mechanism of Action

• Binds GHRH receptors on somatotrophs in the anterior pituitary, stimulating GH release.
• DAC prolongs circulation time, maintaining steady GH pulses without disrupting normal circadian peaks and valleys.
• Elevated GH induces hepatic IGF-1 production, driving anabolic, metabolic, and tissue repair effects.

Indications
(Investigational; not FDA-approved):

Growth Hormone Deficiency (GHD)
Body Composition Improvement (increased lean mass, reduced fat)
Enhanced Recovery and Repair
Sleep and Anti-Aging Applications

Ipamporelin

Ipamorelin

Tesamorelin

s